

Long-term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Lirentelimab, a Monoclonal Antibody Against Siglec-8

Kathryn A. Peterson MD¹, Mirna Chehade MD MPH², Joseph A. Murray MD³, Gary W. Falk MD⁴, Nirmala Gonsalves MD⁵, Robert M. Genta MD⁶, Marc E. Rothenberg MD PhD⁷, Adam C. Bledsoe MD³, Sandy R. Durrani MD⁷, Michael Vaezi MD⁸, Camilla Shaw BSN RN⁹, Henrik S. Rasmussen MD PhD⁹, Bhupinder Singh MD⁹, Alan T. Chang⁹, Amol P. Kamboj MD⁹, Ikuo Hirano MD⁵, Evan S. Dellon MD MPH¹⁰

¹University of Utah, Salt Lake City, UT; ²Icahn School of Medicine at Mount Sinai, New York, NY; ³Mayo Clinic Rochester, Rochester, MN; ⁴University of Pennsylvania, Philadelphia, PA; ⁵Northwestern University, Chicago, IL; ⁶Baylor College of Medicine, Houston, TX; ⁷Division of Allergy and Immunology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ⁸Vanderbilt University, Nashville, TN; ⁹Allakos, Inc., Redwood City, CA.; ¹⁰University of North Carolina, Chapel Hill, NC

DDW 2021

Virtual


May 21st – 23rd 2021

#539

Disclosures

- Dr. Kathryn Peterson is an investigator in the ENIGMA study
- Lirentelimab is an investigational drug candidate and is not FDA/EMA approved
- This study is in progress. Data presented are current as of 3/3/2021

Eosinophilic Gastrointestinal Diseases (EGIDs)




EG, EoD, EoE

Chronic Eosinophilic Inflammation of the Stomach, Duodenum, or Esophagus

- Eosinophils and mast cells are important drivers of disease
- Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia
- No FDA approved treatment for EG, EoD, or EoE
- Current standard of care: diet and/or steroids

Lirentelimab (AK002) Targets Siglec-8 on Eosinophils and Mast Cells



ENIGMA Phase 2 Study Summary

INCLUSION CRITERIA

- Patient-reported active moderate-to-severe symptoms per the **EG/EoD Questionnaire**[®]
 - Captures the symptoms of EG/EoD patients on a daily basis
 - Measures 8 symptoms each on a scale of 0-10; Total Symptom Score: (TSS) 80 points
 - Abdominal pain - Loss of appetite
 - Nausea - Abdominal cramping
 - Vomiting - Bloating
 - Early satiety - Diarrhea
 - Symptom criteria: weekly average ≥ 3 to 10 for abdominal pain, nausea, or diarrhea for at least 2 weeks
- Biopsy-confirmed EG and/or EoD
 - **EG**: ≥ 30 eos/hpf in 5 hpfs (stomach)
 - **EoD**: ≥ 30 eos/hpf in 3 hpfs (duodenum)

STUDY DESIGN

- Phase 2 multi-center, randomized, double-blind, placebo-controlled study
- 65 Patients – 3 arms, 4 monthly doses
 - 21 patients 0.3, 1.0, 3.0, 3.0 mg/kg liletelimab
 - 22 patients 0.3, 1.0, 1.0, 1.0 mg/kg liletelimab
 - 22 patients placebo
- Primary endpoint: Mean % reduction in tissue eosinophils from baseline to day 99
- Secondary endpoints
 - % Treatment responders ($>75\%$ reduction in tissue eosinophil counts AND $>30\%$ reduction in symptoms (TSS) from baseline to 2 weeks post-last dose)
 - Mean % reduction in TSS from baseline to 2 weeks post-last dose

RANDOMIZED STUDY RESULTS

Prespecified Endpoints		liletelimab (n=39)	Placebo (n=20)
1° - Tissue Eosinophils	% Δ	-95%	+10%
	p-value	<0.0001	-
2° - Treatment Responders	%	69%	5%
	p-value	0.0008	-
2° - TSS	% Δ	-53%	-24%
	p-value	0.0012	-

- All primary and secondary endpoints met in the first randomized trial in patients with EG and EoD
- Generally well tolerated

Open-Label Extension (OLE) Study Aim & Design

- **Study Aim**

- Determine safety and efficacy of long-term use of lircatelimab for treatment of EG and/or EoD

- **Study Design**

- Patients who completed ENIGMA had the option to receive lircatelimab in an OLE study
- Patients enrolled in the OLE received up to 26 monthly lircatelimab infusions, administered intravenously every 28 days, titrated up to 3.0 mg/kg
- Patients underwent an upper endoscopy with biopsy on Days 323 (week 46) and 659 (week 94) from entering ENIGMA

OLE Interim Analysis

- **Patient Population**

- 58 of 59 eligible patients entered the OLE study
- As of 3/3/2021,
 - 34 patients ongoing
 - 26 patients have completed ≥ 94 weeks, average ~ 104 weeks
 - 8 patients with < 94 weeks, average ~ 82 weeks
 - 24 patients no longer on treatment, average of ~ 49 weeks

Baseline Characteristics


Patient Characteristics		Enrolled in OLE (N=58)
Age, years Mean (Range)		41 (18-74)
Female		60%
White		93%
GI ^a Eosinophils/hpf, Mean (Range)		74 (33-201)
GI ^a Mast Cells/hpf, Mean (Range)		60 (20-114)
Total Symptom Score [0-80], Mean (Range)		32 (6-61)
% of Patients (n) by AEC ^b /μL	<500	69% (40)
	≥500	31% (18)

a Gastrointestinal; Gastric (5 hpf) or duodenum (3 hpf) site with highest eosinophil or mast cell counts

b AEC: Absolute Eosinophil Count

Substantial Symptom Improvement Over Time

EG/EoD-PRO Total Symptom Score (n=55)




Change in Symptoms Over Time

Total lirentelimab Exposure (Weeks) ^a	TSS Mean Change from ENIGMA BL		
	Baseline	Absolute	Percent
13-14 (n=55)	32	-15	-51%
51-52 (n=38)	34	-22	-66%
93-94 (n=25)	35	-26	-75%

Change in Symptom Response Rate Over Time

Total lirentelimab Exposure (Weeks) ^a	% of Patients (n) by TSS Improvement		
	≥50%	≥70%	≥90%
13-14 (n=55)	58% (32/55)	25% (14/55)	15% (8/55)
51-52 (n=38)	74% (28/38)	55% (21/38)	18% (7/38)
93-94 (n=25)	84% (21/25)	64% (16/25)	40% (10/25)


Symptom Response Rate in Patients with ≥ 94 Weeks of Lirentelimab Treatment



Improvement Across All Symptoms

EG/EoD-PRO Symptom Score


Lirentelimab Patients with ≥ 94 Weeks of Treatment (n=25)



Sustained Histologic Remission on Lirentelimab


Proportion of Patients Meeting Histologic Remission Criteria

Eosinophils ≤ 4 /hpf (Stomach) and/or ≤ 15 /hpf (Duodenum)^a



^a Only patients enrolled in OLE displayed at day 99. 37/39 (95%) lirentelimab patients and 3/20 (15%) placebo patients met histologic remission criteria (predefined as <30 eos/hpf.) at the end of ENGIMA; SOURCE: Dellon ES, et al. New England Journal of Medicine. 2020;383:1624-34.

Sustained Depletion of Blood Eosinophils



Safety Summary

Treatment-Emergent AEs in >5% of Patients

% of Patients, (n)	Total (n=58)
Infusion related reaction	33% (19)
Headache	16% (9)
Nasopharyngitis	16% (9)
Nausea	12% (7)
Anxiety	10% (6)
Blood creatine phosphokinase increased	10% (6)
Diarrhea	10% (6)
Influenza	10% (6)
Rash	9% (5)
Sinusitis	9% (5)
Urinary tract infection	9% (5)
Anemia	7% (4)
Fatigue	7% (4)
Hypertension	7% (4)
Neutrophilia	7% (4)
Oropharyngeal pain	7% (4)
Vomiting	7% (4)

- Generally well-tolerated
- Most common AE was mild to moderate infusion related reactions (IRR)
 - All were mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness)
 - Mostly on first two infusions, greatly reduced or does not occur on subsequent infusions (prior to prednisone pre-treatment protocol)
 - No IRRs in 20 patients who received single-dose oral prednisone night before first infusion
- No drug-related serious AEs in OLE

Summary

- Long-term treatment with lirentelimab results in sustained histologic & symptomatic improvements in patients with EG and/or EoD through week 94
 - Sustained response of blood and tissue eosinophil depletion
 - Symptomatic responses improved with increased duration of treatment
- Long-term treatment with lirentelimab was generally well-tolerated
- Additional lirentelimab studies:
 - Phase 3 randomized trial in EG and/or EoD (NCT04322604)
 - Phase 2/3 randomized trial in EoE (NCT04322708)

We thank the patients who participated in this study, the investigators, and all study staff